Target
Topoisomerase-I (Top1)
2 abstracts
Abstract
A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation.Org: University of California, Irvine Chao Family Comprehensive Cancer Center, Division of Cancer Treatment and Diagnosis National Cancer Institute,
Abstract
Skin adverse events of anti-cancer treatments: An examination of drug-AE associations.Org: La Roche-Posay International, Levallois-Perret, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, Memorial Sloan Kettering Cancer Center,